Dmytro Kharkov

Candel Therapeutics Inc presents new extended follow-up phase 3 data for CAN-2409 in prostate cancer

Candel Therapeutics Inc presents new extended follow-up phase 3 data for CAN-2409 in prostate cancer
Candel Therapeutics updates CAN-2409 data

Candel Therapeutics, Inc. announced the release of new extended follow-up data from its phase 3 trial evaluating aglatimagene besadenovec (CAN-2409) in patients with localized prostate cancer.

The results, presented at the #AUA26 meeting, provide fresh insights into the efficacy and durability of its investigational immunotherapy. The company continues to advance CAN-2409 as a potential treatment for prostate cancer, attracting attention from both clinicians and investors. Further details are available through the official presentation link provided by Candel Therapeutics, Inc.

Earlier this year, Candel Therapeutics CEO called for prioritizing patient engagement to accelerate drug discovery during a panel at BioEquityEurope. The company also marked a leadership milestone as Chief Regulatory Officer Susan Stewart was named among RAPSorg 50 for 50, recognizing regulatory excellence. These developments reflect Candel's recent corporate and industry recognition.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.